
Ahmedabad Plane Crash: Social media users allege Air India CEO's post-crash speech was plagiarised
Campbell Wilson, CEO and Managing Director of Air India, released a video statement following the tragic crash in Ahmedabad last Thursday. His delivery was solemn, and the message appeared sincere. However, social media users have alleged that the speech was largely copied from American Airline CEO's statement earlier this year. As per social media reports, the Air India CEO's speech was nearly identical to one given by American Airlines CEO Robert Isom earlier this year, following a fatal crash in the United States.
— beastoftraal (@beastoftraal) Isom had spoken in response to a January 30, 2025 mid-air collision near Washington D.C., where a commercial jet collided with a military helicopter, resulting in the deaths of at least 67 people.
Alleged Copying of Statement Some social media users have alleged that Wilson's statement included lines such as: 'This is a difficult day for all of us... Our efforts are now focused entirely on the needs of our passengers, crew members, their families, and loved ones.'
These exact phrases—and the broader structure—mirror those used by Isom in his address after the American Airlines Flight 5342 accident, in which a Bombardier CRJ700 collided with a U.S. Army Black Hawk helicopter near Ronald Reagan Washington National Airport.
While Isom's message was widely praised at the time for its emotional sincerity, the repetition of those words in a different context has led to public backlash against Air India, with critics accusing the airline of insincerity and lack of originality in its crisis communication. One online comment read: 'Not ideal to see a copied message after such a tragic event.'
India's Worst Aviation Tragedy in Years The crash of Air India Flight AI-171 marks one of the deadliest aviation disasters in Indian history. The Boeing 787-8 Dreamliner, en route to London Gatwick, crashed shortly after taking off from Ahmedabad airport. There were 230 passengers and 12 crew members on board, including nationals from India, the UK, Portugal, and Canada.The aircraft tragically came down inside the BJ Medical College campus, causing further devastation. Many of those who lost their lives were not passengers, but rather students, medical staff, and local residents in the Meghaninagar area surrounding the crash site.
Air India and its parent company, Tata Group, will jointly provide over ₹1.25 crore in financial assistance to the families of those killed in the Ahmedabad air disaster. This includes ₹1 crore from Tata Sons and an interim ₹25 lakh from the airline itself.
Disclaimer: This article is based on a user-generated post on X. ET.com has not independently verified the claims made in the post and does not vouch for their accuracy. The views expressed are those of the individual and do not necessarily reflect the views of ET.com . Reader discretion is advised.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
3 minutes ago
- Business Standard
Britannia Q1 profit misses estimates, sees early signs of urban recovery
Britannia Industries posted first-quarter profit below estimates on Tuesday, but the Indian biscuit maker said urban consumption - dull for a few quarters - is picking up. The seller of 'Marie Gold' and 'Bourbon' biscuits joins other domestic consumer goods makers such as Hindustan Unilever and ITC in forecasting early signs of a recovery in urban demand, aided by easing local inflation. India's annual retail inflation slowed every month in the quarter, easing to a six-year low in June at 2.1 per cent. That helped spur a "marginal uptick in consumption across both urban and rural markets," said Varun Berry, managing director and chief executive. Britannia's quarterly sales grew 9.8 per cent to ₹4,535 crore ($516.5 million). The firm had previously flagged rise in popular demand for packaged food and confectionery items such as croissants, wafers and flavoured shakes - usually more likely to be bought on impulse. But total spends rose 10.4 per cent, led by a 15 per cent jump in raw material costs. Britannia has been hiking prices to partly offset the higher costs of raw materials such as cocoa, flour and palm oil. Profits in the reported quarter came in at ₹521 crore, up 3 per cent on-year, but below analysts' average estimate of ₹570 crore rupees, according to data compiled by LSEG.
&w=3840&q=100)

Business Standard
3 minutes ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
&w=3840&q=100)

Business Standard
3 minutes ago
- Business Standard
P B Balaji, a CFO who plays with a straight bat, now captains JLR
Balaji's rise to the top spot at JLR as its CEO comes at a time when the company is in a transition phase, lining up plans for more electric vehicles Shine Jacob Chennai Listen to This Article His career moves across the world — from countries like Switzerland and Singapore to cities like London — meant his daughter had to switch nine schools in just 15 years. This is just one glimpse into the lesser-known personal side of the otherwise career-oriented Pathamadai Balachandran Balaji, who was elevated as the first Indian chief executive officer of Tata Motors-owned luxury carmaker Jaguar Land Rover (JLR) on Monday. However, his life is about more than just boardroom talks and business growth. Balaji, in his mid-50s, is a die-hard cricket enthusiast and an admirer of Virat Kohli, yet chooses not to